Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
Status:
Completed
Trial end date:
2017-11-25
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, double-dummy, parallel group study to compare once
daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung
function in subjects with COPD and a Low Peak Inspiratory Flow Rate.